Taking Immunotherapy to the Next Level

For cancer and infectious disease

Our Vision

Gritstone’s goal is to develop groundbreaking immunotherapies for cancers and infectious diseases. Our approach focuses on generating a therapeutic immune response in these patients by unleashing the natural power of a patient’s immune system to recognize and destroy tumors or virally infected cells. It is well-established that one fundamental driver of an effective immune response is T cell recognition of abnormal cells and the proliferation of sufficient quantities of T cells to drive a potent attack against these cells, whether they are cancerous or virally infected. Inspired by this, we developed two platforms: 1) EDGE™, a best-in-class artificial intelligence driven platform to accurately identify T cell targets; and 2) unique delivery systems designed to stimulate the immune system and drive generation of T cells and neutralizing antibodies (nAbs) against the selected targets. Through these platforms, we have developed a portfolio of immunotherapies designed to effectively instruct the immune system to recognize and attack these targets. We believe that activating and directing the immune system in this unique way can offer an important opportunity to extend the benefits of immunotherapy to more patients.

Read More

What is a Tumor Antigen?

A small protein on the surface of a tumor cell that functions as the target for T cell mediated tumor death.


Antigens restricted to a certain normal cell type or lineage

Shared Tumor-Associated Antigens

Antigens present in normal cells and overexpressed in cancer cells

Shared Tumor-Specific Antigens

Antigens found in testis and tumor tissue that are functionally tumor specific

Tumor-Specific Neoantigens

Antigens derived from mutated proteins in tumor cells

Increasing Tumor Specificity
decor-left decor-right

Engaging the Immune System Against Cancer

Leveraging our artificial intelligence Gritstone EDGE™ platform, as well as our expertise in cancer genomics, Gritstone is developing multiple immunotherapies designed to direct a robust immune response to neoantigens. We are developing two key classes of tumor-specific neoantigen product candidates to treat patients with cancer.


Many tumor mutations are unique to each individual patient. For patients with neoantigens arising from patient-specific mutations, we believe that an immunotherapy made specifically for each patient has the potential to drive a potent immune response. GRANITE is Gritstone’s investigational individualized immunotherapy.

Learn More


Some cancer mutations, known as driver mutations, recur between different cancer patients. Neoantigens that arise from these driver mutations and are shared between selected patients may be able to be used for an off-the-shelf neoantigen therapy. SLATE is Gritstone’s investigational off-the-shelf immunotherapy.

Learn More

Engaging the Immune System Against Infectious Disease

COVID-19 Prevention

First generation COVID-19 vaccines focused on eliciting a strong neutralizing antibody response against the surface Spike protein of SARS-CoV-2, the virus that causes COVID-19, and they have been shown to offer good initial protection; however, antibody responses may wane over time. Additionally, mutations in the Spike protein are now appearing and spreading throughout the world, and some have the potential to reduce the neutralizing efficiency of the antibody response. T cells offer a key second layer of defense and may provide longer, more robust immunity. Using both Spike and other validated viral antigens that have been identified through studies of COVID-19 patients, as well as our platform technologies, Gritstone is developing a vaccine against COVID-19 that has the potential to maximize both T cell and antibody responses.

Learn More

Human Immunodeficiency Virus (HIV) Treatment

Gritstone and Gilead Sciences established a collaboration to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a curative treatment for human immunodeficiency virus (HIV) infection. The companies are developing an HIV-specific therapeutic vaccine using Gritstone’s proprietary prime-boost vaccine platform, comprised of self-amplifying mRNA (samRNA) and adenoviral vectors.

Learn More
Pleasanton, CA

Gritstone’s Pleasanton facility houses our manufacturing capabilities and is fully equipped with multiple clean rooms, quality control and assurance, and development labs.

Emeryville, CA

Gritstone’s Emeryville facility is our corporate headquarters and includes our immunotherapy platform research lab and development team.

Cambridge, MA

Gritstone’s Cambridge facility includes our GMP sequencing lab, immune monitoring, and mass spec immunopeptidomics capabilities.

Our Facilities

With antigen-specific immunotherapy products, there are many areas of development that require exceptional expertise and execution. Each of Gritstone’s three facilities have specialized capabilities and personnel with the technical know-how that we believe is required to build the next generation of targeted immunotherapies.

Meet Our Leadership

Gritstone has assembled a group of distinguished scientific founders and advisers, a highly experienced leadership team, and a seasoned board of directors to tackle fundamental challenges at the intersection of cancer genomics and immunotherapy.

Learn More
Andrew Allen, M.D., Ph.D.
Co-founder, President and Chief Executive Officer
Celia Economides
Executive Vice President and Chief Financial Officer
Matthew Hawryluk, Ph.D.
Executive Vice President and Chief Business Officer
Erin E. Jones, M.S.
Executive Vice President and Chief Operating Officer
Karin Jooss, Ph.D.
Executive Vice President and Head of Research & Development
Stacy Proctor
Senior Vice President and Head of People
Vijay Yabannavar, Ph.D.
Executive Vice President and Chief Technical Development Officer

Join Our Team

At Gritstone, we are committed to progressing the field of immunotherapy. One of our goals to eradicate cancer by initially developing personalized immunotherapies that focus on the unique and individual nature of a patient’s tumor. Another goal is to combat infectious diseases. Our first infectious disease program is designed to halt the current pandemic and prevent COVID-19 with a second generation vaccine, and our second program is being developed in collaboration with Gilead Sciences for the treatment of HIV. Our dynamic team combines novel science with a focus on teamwork, and we are looking for passionate, innovative people to join us.

Join Our Team